Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD

PLoS Medicine

Volumn 2, Issue , 2005, Pages 0244-0252

  Haubner, Roland ^a,b   Weber, Wolfgang A ^a,c   Beer, Ambros J ^a   Vabuliene, Eugenija ^a   Reim, Daniel ^a   Sarbia, Mario ^a   Becker, Karl Friedrich ^a   Goebel, Michael ^a   Hein, Rüdiger ^a   Wester, Hans Jürgen ^a   Kessler, Horst ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOARGINYLGLYCYLASPARTIC ACID F 18; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CYCLOPEPTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROGALACTO RGD; FLUOROGALACTO-RGD; GALACTOSE;

ACCURACY; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; VASCULARIZATION; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; GALACTOSE; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MELANOMA; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 18244376347     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020070     Document Type: Article

References (54)

1. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100.
2. Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2: 83-90.
3. Felding-Habermann B (2003) Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20: 203-213.
4. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, et al. (1994) Integrin alpha(v)beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164.
5. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571.
6. Dredge K, Dalgleish AG, Marriott JB (2002) Recent developments in antiangiogenic therapy. Expert Opin Biol Ther 2: 953-966.
7. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, et al. (2001) Overview of angiogenesis: Biological implications for antiangiogenic therapy. Semin Oncol 28: 94-104.
8. Cherrington JM, Strawn LM, Shawver LK (2000) New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Adv Cancer Res 79: 1-38.
9. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, et al. (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822.
10. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, et al. (2002) alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98: 690-697.
11. Teti A, Migliaccio S, Baron R (2002) The role of alphaVbeta3 integrin in the development of osteolytic bone metastases: A pharmacological target for alternative therapy? Calcif Tissue Int 71: 293-299.
12. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
13. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407.
14. Legler DF, Johnson-Leger C, Wiedle G, Bron C, Imhof BA (2004) The alpha v beta 3 integrin as a tumor homing ligand for lymphocytes. Eur J Immunol 34: 1608-1616.
15. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, et al. (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6: 3056-3061.
16. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, et al. (1999) N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42: 3033-3040.
17. Matter A (2001) Tumor angiogenesis as a therapeutic target. Drug Discov Today 6: 1005-1024.
18. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, et al. (2002) Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis 5: 237-256.
19. Smith JW (2003) Cilengitide Merck. Curr Opin Investig Drugs 4: 741-745.
20. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H (2004) Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 40: 228-230.
21. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, et al. (1991) Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 291: 50-54.
22. Haubner RH, Wester HJ, Weber WA, Schwaiger M (2003) Radiotracerbased strategies to image angiogenesis. Q J Nucl Med 47: 189-199.
23. Haubner R, Wester HJ (2004) Radiolabeled tracer for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 10: 1439-1455.
24. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, et al. (2001) Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42: 326-336.
25. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, et al. (1999) Radiolabeled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 40: 1061-1071.
26. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, et al. (2001) Noninvasive imaging of alpha(v)beta3 integrin expression using 18Flabeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61: 1781-1785.
27. 18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15: 61-69.
28. Cheresh DA, Spiro RC (1987) Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 262: 17703-17711.
29. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA (1992) Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 89: 2018-2022.
30. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
31. Ziegler SI, Pichler BJ, Boening G, Rafecas M, Pimpl W, et al. (2001) A prototype high-resolution animal positron tomograph with avalanche photodiode arrays and LSO crystals. Eur J Nucl Med 28: 136-143.
32. Vartanian RK, Weidner N (1994) Correlation of intratumoral endothelial cell proliferation wiht microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 144: 1188-1194.
33. Weber WA, Ziegler SI, Thodtman R, Hanauske AR, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40: 1771-1777.
34. Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, et al. (1991) Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcimoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci U S A 88: 5818-5823.
35. 99mTc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin 43: 26-32.
36. Takagi J, Petre BM, Walz T, Springer TA (2002) Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110: 599-611.
37. 3-octreotide by conjugation with carbohydrates. Bioconjug Chem 13: 1021-1030.
38. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, et al. (2002) Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: The effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 29: 28-38.
39. Wester HJ, Schottelius M, Poethko T, Bruus-Jensen K, Schwaiger M (2004) Radiolabeled carbohydrated somatostatin analogs: A review of the current status. Cancer Biother Radiopharm 19: 231-244.
40. Thumshirn G, Hersel U, Goodman SL, Kessler H (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 9: 2717-2725.
41. 18F-labeled RGD and octreotide analogs. J Nucl Med 45: 892-902.
42. Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R, et al. (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono-and multimeric peptides via oxime formation. Radiochim Acta 92: 317-327.
43. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31: 11-19.
44. 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 31: 1081-1089.
45. 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med 45: 1776-1783.
46. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, et al. (1998) Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer. Clin Cancer Res 4: 2625-2634.
47. 18F-Galacto-RGD. J Nucl Med. 46: 184-189.
48. Meyer GJ, Waters SL, Coenen HH, Luxen A, Maziere B, et al. (1995) PET radiopharmaceuticals in Europe: Current use and data relevant for the formulation of summaries of product characteristics (SPCs). Eur J Nucl Med 22: 1420-1432.
49. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, et al. (1998) Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4: 623-626.
50. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, et al. (2000) Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 44: 433-439.
51. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, et al. (2003) Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 63: 5838-5843.
52. Janssen MLH, Oyen WJG, Massuger LFAG, Frielink C, Dijkgraaf I, et al. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor imaging. Cancer Biother Radiopharm 17: 641-646.
53. 18F-labeled dimeric RGD peptide. Mol Imaging 3: 96-104.
54. Chen X, Liu S, Hou Y, Tohme M, Park R, et al. (2004) MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6: 350-359.